Holds one active US DMF for rifamycin, filing since 2008. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds 3 active US DMFs and one valid CEP for rifamycin, filing since 2021.
Holds one active US DMF for rifamycin, filing since 2021. Its 2023 FDA inspection closed as NAI.
Holds 3 active US DMFs for rifamycin, filing since 2009. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Holds 4 active US DMFs for rifamycin, filing since 2010. Its 2025 FDA inspection closed as VAI.
Holds one valid CEP for rifamycin, filing since 2026. Its 2021 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for rifamycin, filing since 2014.
Registered with DAV (Vietnam) for rifamycin. Its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free